Purified THC/CBD Oil Dramatically Lowers Dementia Agitation

A new study demonstrates that a specialized oral THC/CBD medical oil formulation significantly and rapidly reduces end-of-life agitation in late-stage dementia patients.

Summary: A new study demonstrates that a specialized oral THC/CBD medical oil formulation significantly and rapidly reduces end-of-life agitation in late-stage dementia patients. Tracking 120 hospice-eligible individuals, the LiBBY trial revealed a significant 6.27-point greater reduction in Cohen-Mansfield Agitation Inventory scores compared to placebo within two weeks. Ultimately, nearly 90% of active-arm patients displayed sustained behavioral improvement with safety profiles matching placebo, offering a highly effective, humane alternative to traditional heavy sedatives.

Key Facts: Unprecedented Response Rate: An extraordinary 87.2% of advanced dementia patients treated with the specialized medical THC/CBD compound showed significant behavioral improvement by the end of the 12-week study, a level of success rarely seen in psychiatric trials for dementia. Rapid-Acting Calming Effect: The oral oil suspension was formulated to digest quickly, achieving a significant 6.27-point greater reduction in mean agitation scores on the Cohen-Mansfield Agitation Inventory (CMAI) compared to the placebo group within just 14 days. Targeted Hospice Focus: The Phase 2 LiBBY trial specifically studied 120 hospice-eligible participants (mean age of 80) across 10 U.S. medical centers, conducting clinical visits entirely in the patients’ homes to avoid the distress of hospital travel.

Rigorous Medical Supervision: The researchers issued a critical warning that these clinical benefits cannot be replicated with over-the-counter or dispensary cannabis products, which are completely unregulated and vary dangerously in their purity, dosing, and composition.